The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
Alan P. Venook
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Onyx (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Halozyme; Merck Serono; Roche
Donna Niedzwiecki
No Relationships to Disclose
Federico Innocenti
Consulting or Advisory Role - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Royalties from the Mayo Foundation on the UGT1A1 testing
Briant Fruth
No Relationships to Disclose
Claire Greene
No Relationships to Disclose
Bert H. O'Neil
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Genentech/Roche; Lilly/ImClone; Sanofi
Speakers' Bureau - Amgen
James Edward Shaw
No Relationships to Disclose
James Norman Atkins
No Relationships to Disclose
Laura E. Horvath
No Relationships to Disclose
Blase N. Polite
Speakers' Bureau - Bayer/Onyx
Research Funding - Merck
Other Relationship - Gerson Lehrman Group
Jeffrey A. Meyerhardt
Research Funding - Biothera (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst)
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Gilead Sciences; Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Merrimack; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst); Polaris (Inst); Sanofi (Inst)
Richard M. Goldberg
Honoraria - Baxter; Biothera; Immunocare Therapies; kanghong Pharma; Lilly; Momenta Pharmaceuticals; Novo Nordisk; Sanofi
Research Funding - Bayer (Inst); Immunomedics (Inst); Merck (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Baxter; Merck KGaA; Sanofi
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical
Speakers' Bureau - Genomic Health
Charles David Blanke
No Relationships to Disclose
Richard L. Schilsky
No Relationships to Disclose
Robert J. Mayer
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - CASI Pharmaceuticals
Monica M. Bertagnolli
No Relationships to Disclose
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Celgene; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche